The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

"Bob Dean would have been completely protected," said one advocate about how the law change would affect nursing home ...

We published the book "Demystifying Psychiatry" in 2010. Although basic principles of psychiatric treatment remain unchanged, ...

Gardiner Harris’s investigation of Johnson & Johnson explores the many ways corporate greed and weak regulations fail to ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Changes to nursing home survey protocols — set to take effect April 28 — are putting a sharper focus on resident rights, ...